Floatz logo

Herzuma

Metastatic Malignant Solid Neoplasm

National Cancer Institute (NCI)Phase 2Active
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
73/ 100

Competitive context

74 Active assets in the Metastatic Malignant Solid Neoplasm cohort.

Asset / SponsorPhaseRating
Ipilimumab
Federation Francophone de Cancerologie Digestive
Phase 3BB
Nivolumab
Fred Hutchinson Cancer Center
Phase 3BB
Abemaciclib
National Cancer Institute (NCI)
Phase 3B
TEONANACATL
University of Washington
Phase 2B
Carboplatin
Revolution Medicines, Inc.
Phase 2B

View all 50 →

Same molecule, other indications

Herzuma is also rated in:

Unresectable Malignant Solid NeoplasmDormant
B
Indicative ·
58 / 100
View asset →
HER2 Gene MutationDormant
B
Indicative ·
57 / 100
View asset →
breast cancerDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →